01:19 PM EDT, 09/09/2024 (MT Newswires) -- Femasys ( FEMY ) said Monday it has received 510(k) clearance from the US Food and Drug Administration for FemChec, a tool designed for controlled delivery of contrast to check the status of fallopian tubes.

It is part of the company's non-surgical permanent birth control method, dubbed FemBloc, Femasys ( FEMY ) said.

The company added that it will continue to work with the regulator as FemBloc moves through a late-stage trial that is currently enrolling.

Price: 1.07, Change: -0.01, Percent Change: -0.47